Literature DB >> 21431854

Why does NAFLD predict type 2 diabetes?

Guido Lattuada1, Francesca Ragogna, Gianluca Perseghin.   

Abstract

Based on the "lipotoxic" hypothesis, the free fatty acid flux from the excessive amount of adipose tissue toward the peripheral tissues would induce the development of insulin resistance especially when the triglyceride storage or the concentration of intermediate fat metabolites (diacylglycerides, ceramides) within the cytoplasm of these cells become excessive. Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver damage, ranging from simple steatosis to steatohepatitis and advanced fibrosis. NAFLD is associated with general and intra-abdominal obesity and with a reduced ability of insulin to stimulate metabolic pathways in the liver itself and in other tissues. There are animal models and models in human diseases sustaining the hypothesis that a primary hepatic disease may determine the development of type 2 diabetes (T2DM). Epidemiologic data generated on surrogate markers of NAFLD (transaminases and γ-glutamyltransferase), semiquantitative assessment of fatty liver (ultrasound), and surrogate algorithms of NAFLD also support a causative effect of NAFLD on the risk to develop T2DM. In spite of the presence of these indirect associations, a clear-cut link between NAFLD and abnormal β-cell function is yet to be reported. Therefore, more data are warranted to prove what is considered a likely causative relationship between NAFLD and T2DM.

Entities:  

Mesh:

Year:  2011        PMID: 21431854     DOI: 10.1007/s11892-011-0190-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.

Authors:  G Perseghin; V Mazzaferro; L P Sereni; E Regalia; S Benedini; E Bazzigaluppi; A Pulvirenti; A A Leão; G Calori; R Romito; D Baratti; L Luzi
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease.

Authors:  Gianluca Perseghin; Riccardo Bonfanti; Serena Magni; Guido Lattuada; Francesco De Cobelli; Tamara Canu; Antonio Esposito; Paola Scifo; Georgia Ntali; Federica Costantino; Laura Bosio; Francesca Ragogna; Alessandro Del Maschio; Giuseppe Chiumello; Livio Luzi
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-05-09       Impact factor: 4.310

Review 3.  Glucose metabolism in cirrhosis: a review with some perspectives for the future.

Authors:  A S Petrides; R A DeFronzo
Journal:  Diabetes Metab Rev       Date:  1989-12

4.  Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism.

Authors:  N J van der Zijl; G H Goossens; C C M Moors; D H van Raalte; M H A Muskiet; P J W Pouwels; E E Blaak; M Diamant
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

5.  Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults.

Authors:  C-H Kim; J-Y Park; K-U Lee; J-H Kim; H-K Kim
Journal:  Diabet Med       Date:  2008-03-13       Impact factor: 4.359

6.  Cirrhosis and diabetes. I. Increased incidence of diabetes in patients with Laennec's cirrhosis.

Authors:  H O Conn; W Schreiber; S G Elkington; T R Johnson
Journal:  Am J Dig Dis       Date:  1969-12

7.  Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects.

Authors:  Devjit Tripathy; Priya Mohanty; Sandeep Dhindsa; Tufail Syed; Husam Ghanim; Ahmad Aljada; Paresh Dandona
Journal:  Diabetes       Date:  2003-12       Impact factor: 9.461

8.  Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity.

Authors:  A S Petrides; T Stanley; D E Matthews; C Vogt; A J Bush; H Lambeth
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

Review 9.  Cellular mechanism of insulin resistance: potential links with inflammation.

Authors:  G Perseghin; K Petersen; G I Shulman
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

10.  Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins.

Authors:  Abigail Fraser; Mikael Thinggaard; Kaare Christensen; Debbie A Lawlor
Journal:  Liver Int       Date:  2009-08-14       Impact factor: 5.828

View more
  18 in total

Review 1.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

2.  Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women.

Authors:  Giorgio Bedogni; Amalia Gastaldelli; Claudio Tiribelli; Fiorenza Agosti; Alessandra De Col; Rezene Fessehatsion; Alessandro Sartorio
Journal:  J Endocrinol Invest       Date:  2014-06-07       Impact factor: 4.256

3.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

4.  Downregulation of sulfotransferase expression and activity in diseased human livers.

Authors:  Emine B Yalcin; Vijay More; Karissa L Neira; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt; Roberta S King
Journal:  Drug Metab Dispos       Date:  2013-06-17       Impact factor: 3.922

5.  Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease.

Authors:  Gautam K Singh; Bernadette E Vitola; Mark R Holland; Timothy Sekarski; Bruce W Patterson; Faidon Magkos; Samuel Klein
Journal:  J Pediatr       Date:  2012-12-20       Impact factor: 4.406

6.  Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA).

Authors:  Luis A Rodriguez; Alka M Kanaya; Stephen C Shiboski; Alicia Fernandez; David Herrington; Jingzhong Ding; Patrick T Bradshaw
Journal:  Ann Epidemiol       Date:  2021-07-19       Impact factor: 3.797

7.  Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes.

Authors:  Carlos C Barros; Anderson Haro; Fernanda J V P Russo; Ines Schadock; Sandro S Almeida; Rosane A Ribeiro; Emerielle C Vanzela; Valeria P Lanzoni; Flavio C Barros; Milton R Moraes; Marcelo A Mori; Reury F P Bacurau; Martin Wurtele; Antônio C Boschero; Everardo M Carneiro; Michael Bader; Joao B Pesquero; Ronaldo C Araujo
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

8.  ILDR2: an endoplasmic reticulum resident molecule mediating hepatic lipid homeostasis.

Authors:  Kazuhisa Watanabe; Elizabeth Watson; Maria Laura Cremona; Elizabeth J Millings; Jay H Lefkowitch; Stuart G Fischer; Charles A LeDuc; Rudolph L Leibel
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran.

Authors:  Bahareh Amirkalali; Hossein Poustchi; Hossein Keyvani; Mahmood Reza Khansari; Hossein Ajdarkosh; Mansooreh Maadi; Masoud Reza Sohrabi; Farhad Zamani
Journal:  Iran J Public Health       Date:  2014-09       Impact factor: 1.429

10.  Fatty liver increases the association of metabolic syndrome with diabetes and atherosclerosis.

Authors:  Juan G Juárez-Rojas; Aida X Medina-Urrutia; Esteban Jorge-Galarza; Carmen González-Salazar; Eric Kimura-Hayama; Guillermo Cardoso-Saldaña; Rosalinda Posadas-Sánchez; Rocio Martínez-Alvarado; Carlos Posadas-Romero
Journal:  Diabetes Care       Date:  2012-12-18       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.